Proactive Investors - Run By Investors For Investors

Cellmid board members hoover up company stock

Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
board room table surrounded by empty chairs
The board purchases show their confidence in the company's future

Cellmid Ltd (ASX:CDY) has had four of its board members purchase company stock recently with one member buying $1 million worth of shares.

The share purchases were made in a variety of ways including on-market trades and participation in the recent share placement and share purchase plan (SPP).

The board members that increased their holdings were managing director and CEO Maria Halasz and non-executive directors Bruce Gordon, Dr Martin Cross and Dennis Eck.

Eck acquired 2.63 million shares for $1 million, Halasz acquired 263,157 for $100,000, Dr Cross acquired 130,000 shares for $50,400, and Gordon acquired 26,316 shares for $10,000.

READ: Cellmid’s study confirms effectiveness of lead antibody against rare chronic kidney disease

 

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

seeds in a bowl
March 08 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use